<DOC DOCNO="nw/wsj/04/wsj_0468@0468@wsj@nw@en@on">
<ENAMEX TYPE="ORG">G.D. Searle -AMP- Co.</ENAMEX> said <ENAMEX TYPE="ORG">the Food and Drug Administration</ENAMEX> approved the sale of Kerlone , a hypertension drug developed by a joint venture between <ENAMEX TYPE="ORG">Searle</ENAMEX> and a <ENAMEX TYPE="NORP">French</ENAMEX> concern .
<ENAMEX TYPE="ORG">Searle</ENAMEX> , a unit of <ENAMEX TYPE="ORG">Monsanto Co.</ENAMEX> , said the `` beta - blocker '' high - blood - pressure drug Kerlone is the first product to reach the market through <ENAMEX TYPE="ORG">Lorex Pharmaceuticals</ENAMEX> , the <ENAMEX TYPE="GPE">U.S.</ENAMEX> company jointly owned by <ENAMEX TYPE="ORG">Searle</ENAMEX> and <ENAMEX TYPE="ORG">Synthelabo</ENAMEX> , a <ENAMEX TYPE="NORP">French</ENAMEX> pharmaceutical concern owned by <ENAMEX TYPE="GPE">France</ENAMEX> 's <ENAMEX TYPE="ORG">L'Oreal S.A</ENAMEX> .
</DOC>
